Low- and middle-income countries (LMICs) can only attain health equity by eliminating their disproportionate burden of infectious diseases. The Global Innovation Alliance (GIA) was created by BVGH to address this burden with a sustainable public-private partnership model focused on, and driven by, LMICs’ needs. Central to GIA is the belief that lasting solutions emerge from within, and in collaboration with, LMIC research institutions and healthcare systems.
Building on BVGH’s 15+ years of infectious disease partnering, alliance management, and capacity building expertise—through initiatives including the Pool for Open Innovation Against Neglected Tropical Diseases (POINT) and WIPO Re:Search—GIA will:
- Catalyze early-stage research and development (R&D) partnerships—through intellectual property (IP) asset sharing and funding for LMIC scientists—defined by LMIC researchers’ priorities and aligned with endemic countries’ needs.
2. Build and promote clinical trial capabilities and inclusion in LMICs through training programs; publication of LMIC sites’ clinical trial readiness profiles; and facilitation of clinical trial partnerships between LMIC investigators and GIA sponsors and members.
3. Elevate scientific expertise in LMICs—and empower more LMIC scientists to participate in infectious disease R&D—through tailored capacity building and knowledge sharing programs.
4. Communicate program outcomes and impacts to targeted audiences, including but not limited to United States Congress, United Nations agencies, public, and mainstream media.
Alliance sponsors choose how they want to participate in and contribute to GIA. Participation is tailored to each sponsor’s interests, priorities, and assets contributed.
